XBiotech Inc. (XBIT) stock
XBITNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.78−0.07 (-3.78%)
Close on Nov 17, 2026Market cap $54.27MP/E –Yield –
XBiotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
XBiotech's operating income for the twelve months ending Jun 30, 2026 was -$48.22M. For fiscal 2025 it was -$55.69M. The highest annual figure on record is -$9.93M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$55.69M | – |
| FY2024 | Dec 31, 2024 | -$42.47M | – |
| FY2023 | Dec 31, 2023 | -$37.51M | – |
| FY2022 | Dec 31, 2022 | -$34.49M | – |
| FY2021 | Dec 31, 2021 | -$25.08M | – |
| FY2020 | Dec 31, 2020 | -$18.28M | – |
| FY2019 | Dec 31, 2019 | -$31.23M | – |
| FY2018 | Dec 31, 2018 | -$20.99M | – |
| FY2017 | Dec 31, 2017 | -$34.06M | – |
| FY2016 | Dec 31, 2016 | -$52.76M | – |
| FY2015 | Dec 31, 2015 | -$37.51M | – |
| FY2014 | Dec 31, 2014 | -$21.78M | – |
| FY2013 | Dec 31, 2013 | -$9.93M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$29.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.52M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.26M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.16M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.61M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.92M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.67M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.51M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.17M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.12M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.62M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.15M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.51M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.59M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.69M | – |
| Q1 FY2017 | Mar 31, 2017 | -$10.27M | – |
| Q4 FY2016 | Dec 31, 2016 | -$16.44M | – |
| Q3 FY2016 | Sep 30, 2016 | -$12.46M | – |
See a number that looks wrong?